Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

News Conference News TVT 2022

Less Paravalvular Leak With Newer Acurate neo2 TAVI: Registry

Michael O'Riordan

June 13, 2022

News Conference News TVT 2022

Surgical Explant or Redo for TAVI Failures? Some Registry Insights

Michael O'Riordan

June 10, 2022

News Daily News

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

Michael O'Riordan

October 01, 2021

News Conference News TCT 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Michael O'Riordan

October 16, 2020

News Conference News TCT 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Michael O'Riordan

October 15, 2020

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2017

Shelley Wood

July 31, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Daily News

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Michael O'Riordan

February 09, 2017

Advertisement

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Less Paravalvular Leak With Newer Acurate neo2 TAVI: Registry

Surgical Explant or Redo for TAVI Failures? Some Registry Insights

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

TCTMD’s Top 10 Most Popular Stories for July 2017

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content